Alterity in spotlight at medical conferences as MSA clinical research moves toward Phase III planning

Presentations at key medical conferences in May support advancement of Alterity’s lead drug ATH434 into Phase III development for Multiple ... Read More The post Alterity in spotlight at medical conferences as MSA clinical research moves toward Phase III planning appeared first on Stockhead .

Go to News Site